دورية أكاديمية
Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone.
| العنوان: | Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone. |
|---|---|
| المؤلفون: | Piccirillo SG; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK., Spiteri I; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK., Sottoriva A; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA., Touloumis A; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK.; European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge, UK., Ber S; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK., Price SJ; Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK., Heywood R; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK., Francis NJ; Department of Oncology and the Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK., Howarth KD; Hutchison/MRC Research Centre and Department of Pathology, University of Cambridge, Cambridge, UK., Collins VP; Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK., Venkitaraman AR; Department of Oncology and the Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK., Curtis C; Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA., Marioni JC; European Bioinformatics Institute (EMBL-EBI), Wellcome Trust Genome Campus, Hinxton, Cambridge, UK., Tavaré S; Cancer Research UK Cambridge Institute, Li Ka Shing Centre, Cambridge, UK., Watts C; John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK.; Division of Neurosurgery, Department of Clinical Neurosciences, University of Cambridge, Addenbrooke's Hospital, Cambridge, UK. |
| المصدر: | Cancer research [Cancer Res] 2015 Jan 01; Vol. 75 (1), pp. 194-202. Date of Electronic Publication: 2014 Nov 18. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Baltimore, Md. : American Association for Cancer Research Original Publication: Chicago [etc.] |
| مواضيع طبية MeSH: | Brain Neoplasms/*drug therapy , Brain Neoplasms/*pathology , Ependyma/*pathology , Glioblastoma/*drug therapy , Glioblastoma/*pathology , Neoplastic Stem Cells/*pathology , Neural Stem Cells/*pathology, Cell Line, Tumor ; Drug Resistance, Neoplasm ; Humans |
| مستخلص: | Glioblastoma, the most common and aggressive adult brain tumor, is characterized by extreme phenotypic diversity and treatment failure. Through fluorescence-guided resection, we identified fluorescent tissue in the sub-ependymal zone (SEZ) of patients with glioblastoma. Histologic analysis and genomic characterization revealed that the SEZ harbors malignant cells with tumor-initiating capacity, analogous to cells isolated from the fluorescent tumor mass (T). We observed resistance to supramaximal chemotherapy doses along with differential patterns of drug response between T and SEZ in the same tumor. Our results reveal novel insights into glioblastoma growth dynamics, with implications for understanding and limiting treatment resistance. (©2014 American Association for Cancer Research.) |
| References: | Cancer Cell. 2005 Aug;8(2):119-30. (PMID: 16098465) Cancer Cell. 2009 Jan 6;15(1):45-56. (PMID: 19111880) Cancer Cell. 2006 Mar;9(3):157-73. (PMID: 16530701) Cell Cycle. 2006 Mar;5(6):610-4. (PMID: 16582617) Lancet Oncol. 2006 May;7(5):392-401. (PMID: 16648043) Cancer Cell. 2006 May;9(5):391-403. (PMID: 16697959) Methods Enzymol. 2006;411:134-93. (PMID: 16939790) Nature. 2006 Dec 7;444(7120):761-5. (PMID: 17151667) Acta Neuropathol. 2007 Aug;114(2):97-109. (PMID: 17618441) Neuro Oncol. 2007 Oct;9(4):424-9. (PMID: 17622647) Nature. 2008 Oct 23;455(7216):1061-8. (PMID: 18772890) N Engl J Med. 2005 Mar 10;352(10):987-96. (PMID: 15758009) J Neurosci Methods. 2009 Jan 30;176(2):192-9. (PMID: 19215724) J Cell Physiol. 2009 May;219(2):288-300. (PMID: 19115235) Oncogene. 2009 Apr 16;28(15):1807-11. (PMID: 19287454) Cell Stem Cell. 2009 May 8;4(5):440-52. (PMID: 19427293) Cancer Cell. 2009 Jun 2;15(6):514-26. (PMID: 19477430) Cancer Res. 2009 Jun 1;69(11):4682-90. (PMID: 19487286) Cell Stem Cell. 2009 Jun 5;4(6):568-80. (PMID: 19497285) Cell. 2009 Sep 4;138(5):822-9. (PMID: 19737509) Expert Opin Investig Drugs. 2009 Oct;18(10):1549-57. (PMID: 19671039) Clin Cancer Res. 2009 Nov 15;15(22):7092-8. (PMID: 19861433) J Neurooncol. 2010 Feb;96(3):359-67. (PMID: 19655089) J Mol Med (Berl). 2009 Nov;87(11):1087-95. (PMID: 19784875) Cancer Cell. 2010 Jan 19;17(1):98-110. (PMID: 20129251) BMC Cancer. 2010;10:66. (PMID: 20181261) Stem Cells. 2010 May;28(5):851-62. (PMID: 20309962) J Clin Oncol. 2010 Jun 10;28(17):2817-23. (PMID: 20458050) Lancet Neurol. 2010 Jul;9(7):717-26. (PMID: 20610347) BMC Cancer. 2010;10:384. (PMID: 20663133) Genome Biol. 2010;11(7):R76. (PMID: 20649963) Acta Neuropathol. 2011 May;121(5):651-61. (PMID: 21287394) Br J Cancer. 2011 Jun 7;104(12):1810-5. (PMID: 21610702) Methods Enzymol. 2012;506:311-29. (PMID: 22341231) J Exp Med. 2012 Mar 12;209(3):507-20. (PMID: 22393126) Br J Cancer. 2012 Jul 24;107(3):462-8. (PMID: 22722315) Nature. 2012 Aug 23;488(7412):522-6. (PMID: 22854781) Cancer Res. 2013 Jan 1;73(1):41-9. (PMID: 23090114) Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4009-14. (PMID: 23412337) Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):616-22. (PMID: 23540348) Acta Neuropathol. 2014 Feb;127(2):203-19. (PMID: 24154962) Nat Genet. 2000 May;25(1):55-7. (PMID: 10802656) Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10839-44. (PMID: 11517339) Neuron. 2002 Aug 29;35(5):865-75. (PMID: 12372282) Nature. 2004 Feb 19;427(6976):740-4. (PMID: 14973487) Clin Cancer Res. 2004 Jun 1;10(11):3728-36. (PMID: 15173079) Acta Neuropathol. 1994;87(1):47-54. (PMID: 7511316) Cancer Res. 1999 Feb 15;59(4):793-7. (PMID: 10029064) J Mol Med (Berl). 2004 Oct;82(10):656-70. (PMID: 15316624) Nature. 2004 Nov 18;432(7015):396-401. (PMID: 15549107) Nature. 2008 Oct 23;455(7216):1129-33. (PMID: 18948956) N Engl J Med. 2005 Aug 25;353(8):811-22. (PMID: 16120861) |
| معلومات مُعتمدة: | 16700 United Kingdom CRUK_ Cancer Research UK; A14545 United Kingdom CRUK_ Cancer Research UK; C14303/A10825 United Kingdom CRUK_ Cancer Research UK; C1023/A14545 United Kingdom CRUK_ Cancer Research UK; NIHR/CS/009/011 United Kingdom DH_ Department of Health; A10825 United Kingdom CRUK_ Cancer Research UK; 14545 United Kingdom CRUK_ Cancer Research UK; MC_UU_12022/1 United Kingdom MRC_ Medical Research Council; 090340 United Kingdom WT_ Wellcome Trust; G1001522 United Kingdom MRC_ Medical Research Council |
| فهرسة مساهمة: | Indexing Agency: NLM Local ID #: EMS61174. |
| تواريخ الأحداث: | Date Created: 20141120 Date Completed: 20150423 Latest Revision: 20240210 |
| رمز التحديث: | 20240210 |
| مُعرف محوري في PubMed: | PMC4286248 |
| DOI: | 10.1158/0008-5472.CAN-13-3131 |
| PMID: | 25406193 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1538-7445 |
|---|---|
| DOI: | 10.1158/0008-5472.CAN-13-3131 |